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A. INTRODUCTION
Breast cancer is the most common cancer in women in the United States. Endocrine therapy has proven to be beneficial in approximately one-third of breast cancer patients. However, the tumors inevitably progress to a state of hormone insensitivity and no longer respond to conventional endocrine therapies. Therefore, it is necessary to identify other molecular markers to monitor the pathological process of the disease in order to better evaluate patient prognosis and to elucidate molecular mechanism of breast cancer initiation, progression and metastasis in order to develop new reagents for subsequent treatments. The proposed study of TGF-B growth inhibitory signaling pathways in breast carcinogenesis will significantly benefit both of these purposes.
The overall goal of this research project is to explore the roles of TGF-B and its signaling receptors in the initiation, progression and metastasis of breast adenocarcinomas through an investigation of the disregulation of TGF-B signal transduction. TGF-B's are a group of multifunctional polypeptide hormones which play important roles in many normal cellular functions including the regulation of proliferation, differentiation, extracellular matrix deposition, cell adhesion and migration. The effects of TGF-B are highly diverse and cell specific. In normal breast epithelium, TGF-B acts primarily as an inhibitor of proliferation. Loss of the TGF-B growth inhibitory response in these normal cells may lead to a selective growth advantage which in turn could lead to uncontrolled proliferation in a subsequently transformed cell population. Since the TGF-B signaling receptors are crucial components mediating TGF-B growth regulatory effects, alterations in the expression profile of these receptors may be a cause of changes in TGF-B responsiveness in breast epithelial cells. Furthermore, available evidence suggests that the expression of TGF-B receptors may be a target subject to regulation by steroid hormones, such as estrogen. We intend to determine if this type of interactive regulation between two growth signaling pathways in breast epithelial cells, one positive and one negative, plays a significant role in the control of cell proliferation and subsequent tumorigenesis.
The other important aspect of TGF-6 function, besides its growth regulatory activity, is its potent effect on the activation of genes involved in extracellular matrix formation, cell adhesion and migration. The loss of growth inhibitory response to TGF-13, while retaining gene activation responses in breast cancer cells, could give tumors a great growth advantage and metastasis potential. It is possible that different arms of the TGF-B responsiveness (growth regulation vs. induction of specific genes) are controlled by different signaling pathways. A hypothesis will be tested whether the type II receptor is primarily responsible for initiating a cascade toward the growth regulatory pathway while the type I receptor for the gene induction pathway, even though both receptors are simultaneously required for mediating any TGF-B signals across the membrane. Alternatively, the two arms of TGF-B signaling pathways may diverge downstream of the two receptors at the level of substrates/effectors that interact specifically with the individual receptors. We intend to put our efforts on identifying and isolating these cellular components by using several strategies that have been effective in other studies.
In the last twelve months, our work has been focused on two main areas: evaluation of the functional role of the type II TGF-B receptor in breast carcinogenesis and examination of the specific TGF-3 growth responses and their modulation by estrogen in breast cell lines. These studies were proposed as Specific Aims 1 & 2 in the original proposal and the progress in these areas are reported below. We have encountered certain technical difficulties in addressing the remaining questions outlined in the proposal for Year 1-2. Our effort in trying to overcome those difficulties is also reported below.
B. PROGRESS REPORT
Many breast cancer cell lines have lost their responsiveness to the TGF-B growthinhibitory signal to potentially gain a growth advantage. In certain cases, this loss of responsiveness was the result of loss of signaling receptors for TGF-B, particularly the type II receptor (RII). To evaluate whether the loss of the RII consists a key event in the tumorigenic phenotype of those cancerous cells, we examined the role of TGF-B RII in reversing the malignant phenotype of human breast cancer MCF-7 cells in collaboration with Dr. M. Brattain's lab at Medical College of Ohio. Parental MCF-7 cells were insensitive to TGF-13 and expressed undetectable levels type II receptor expression on cell surface. Stable transfection of a RII expression vector yielded three clones with various levels of exogenous R1H mRNA and protein levels. Expression of RH also increased TGF-B binding to RI in all three clones. Proliferation of RII-positive clones was inhibited by exogenous TGF-3 in a dose-dependent manner, whereas the control clones remained TGF-B-insensitive. The RII transfectants were growth arrested in monolayer culture at saturation densities which were 41-66% of that of the Neo controls. They also showed reduced clonogenicity in soft-agarose. Tumorigenecity in ovariectomized estrogensupplemented nude mice was delayed in transfectants with low RII levels. Transfectants expressing high levels of RII showed a large reduction in tumorigenicity as well as a longer delay in tumor formation. Tumor growth was associated with loss of exogenous RII expression in transfectants. These results indicate that when systems for TGF-1 signal transduction are intact, reconstitution of the TGF-B receptor system can lead to reversion of malignancy in breast cancer cells lacking RII (appendix 1).
The conclusion that TGF-B and its signaling receptor RH may play an important role in tumorigenesis has been reinforced by the recent finding that the RER colorectal cancer genotype, which is characteristic of hereditary nonpolyposis colorectal cancers (HNPCC), is closely associated with the loss of RI and consequently an escape from the negative growth regulation "by TGF-13 in those cells. Again, in collaboration with Dr. Brattain's lab, an attempt was made to directly test the importance of RII mutations in RER colon carcinoma cells in determining the malignant phenotype by the restoration of RII expression in those cells. Similar to the studies in MCF-7 cells, stable RII transfectants of the RER+ HCT1 16 cells showed reduced clonogenicity in both monolayer culture and soft agarose; they were growth arrested at a lower saturation density than control cells, indicating the alterations in growth parameters of the transfected cells were due to the acquisition of autocrine-negative activity; tumorigenicity in athymic mice was reduced and delayed. These results indicate that reconstitution of TGF-B autocrine activity by reexpression of RII can reverse malignancy in RER colon cancers, thus further verifying the notion that the malignancy of both breast cancer and HNPCC can be directly associated with the loss of RII expression (ref. 1, appendix 2).
The tasks outlined in the original proposal or Statement of Work also include histological studies of preisolated breast carcinoma specimens and the examination of TGF-3 receptor content in breast primary cultures and cell lines. Progress in undertaking those tasks has been limited primarily due to the lack of certain specific reagents, namely high titer specific antibodies against the type II and type I TGF-3 receptors which are absolutely necessary if the stated goals are to be achieved. We have tested and failed to detect the expression of the two receptors in breast cell lines through either Western blot analysis or histological staining by using all six commercially available antibodies. Those antibodies apparently could only be used to detect the overexpressed type II or type I receptors in receptor cDNA-transfected COS cells. This has been a common problem for all the researchers who have attempted to study the expression of endogenous TGF-B receptors due to their low abundance in almost all cell types and tissues. In an attempt to eventually overcome this difficulty, we have in the past year developed four polyclonal antibodies: three against different domains of the type II TGF-B receptor and one against the type I receptor. We have also established a collaboration with Dr. Carlos L. Arteaga of the Dept. of Medical Oncology at Vanderbilt University, who is an expert in the special field of the roles of TGF-B in breast carcinogenesis, to address this question. Our preliminary results indicate that at least one of the type IH receptor antibodies, raised against the extracellular domain of the receptor, appears to recognize a single band about the right size of the. type II receptor in MCF-7 cells by both immunoprecipitation and Western blot analyses (data not shown). We are in the process of confirming those results by examining several more human cell lines which are known to response to TGF-B and thus presumably express the type II receptor. If this antibody is proven to be capable of detecting the type II receptor in those cell lines, we will extend the study to include the histological examination of the receptor content in both primary breast cells in culture and the preisolated breast carcinoma specimens. We are still in the process of assessing the capability of the anti-type I receptor antibody in recognizing endogenously expressed type I receptor in breast cell lines.
We have initiated studies on the examination of specific TGF-B gene responses and growth responses, and modulation of these effects by estrogen and antiestrogens in breast cell lines, as outlined in the Statement of Work for Year 1-2. The main purpose of this examination is to determine the interactions between the growth-inhibitory pathway of TGF-B and the growthstimulatory pathway of estrogen in both normal and transformed breast epithelial cells. To achieve this goal, we needed to establish a system in which the biological effects of both TGF-B and estrogen are well defined so that the biochemical nature of their pathways could be analyzed at the molecular level. For practical reasons, we initiated our studies on breast cell lines rather than on the primary breast epithelial cell cultures. We have screened a large number of available breast cell lines, including multiple sublines of the MCF-7 cell line, because many of them may have accumulated different genetic alterations while they are in culture for a long peroid of time. We treated those cell lines with TGF-B, estrogen, estrogen plus progestron, or TGF-B plus estrogen, respectively, and measured DNA synthesis using the 3 H-thymidine incorporation assay. Based on those studies, we have found three MCF-7 sublines to be responsive to both the TGF-B growth-inhibitory signal as well as the estrogen growth-stimulatory signal (shown as Fig. 1 and  2 ). In at least two of these MCF-7 sublines, the TGF-B growth-inhibitory effect was significantly reduced by the presence of estrogen, suggesting the estrogen signaling pathway may override the TGF-13 pathway. A separate breast cancer cell line, SKBR3, was found to be non-responsive to either TGF-B or estrogen and has been used as a negative control in our studies. These results established a foundation upon which we could begin the task of dissecting the molecular mechanism of interactions between the two antagonizing pathways in breast epithelial cells. However, before we could study the question of how the interactions between the two pathways occur, we need to elucidate the molecular nature of the TGF-B signaling pathway leading to cell cycle arrest in late G 1 in those cells.
Beyond the level of TGF-B signaling receptors, we still do not have adequete information on how the TGF-B signal is transmitted to cause growth arrest in mammary epithelial cells. Previous examination of TGF-B effects on the cyclin-cdk complexes by us and other groups has shown that at least part of the growth inhibitory effects of TGF-B can be explained by a down regulation of the G 1 cyclin dependent kinases (specifically cdk2 and cdk4) as well as a similar effect on their cyclin partners (specifically cyclin E). These G 1 cdk's and cyclins appear to be essential for cells to progress through the G 1 phase as shown by their temporal expression during the mid to late G1 as well as by dominant negative mutations of certain cdk's (specifically cdk2) which cause growth arrest of cells in G1. These experiments taken together suggest that TGF-B may work through an inhibition of the members of the cell cycle machinery that are essential for GI progression. There has been data of TGF-B inhibition of cell cycle progression that can not be explained simply by cyclin/cdk down regulation. In addition to down regulation of cyclins and their kinase partners, for example, treatment of cells with TGF-B appear to cause accumulation of factors which inhibit cyclin dependent kinase activity. A recently identified molecule, p27, has been shown to inhibit the function of cyclin E/cdk2 complexes upon treatment of cells with TGF-B. In addition to p27, there are several other small proteins, including p15 and p21, which have been recently cloned and shown to inhibit the activities of cyclin/cdk complexes (ref. 2, 3) . p21 is the best characterized of these small inhibitory molecules. It was originally cloned -by three independent approaches: 1) by the two hybrid system using cdk2 as a bait molecule; 2) using a subtractive RNA cloning technique isolating molecules induced by p53; and 3) from microsequencing of a 21kd molecule which associates with the cyclin/cdk complexes upon immunoprecipitation. After the cloning, p21 was found to be induced by p53 and to act as a strong inhibitor of all cyclin/cdk complexes. p21 is present at high levels in senescent cells and overexpression of p21 causes growth arrest of cells in Gl. All these lines of evidence make p21 an excellent candidate for an effector of the TGF-B pathway by acting to inhibit the cyclin kinase activity and cause growth arrest in G1. If this is the case, then p53, a molecule which is known to be a important regulator of GI progression, would also be implicated in the TGF-B growth regulatory pathway.
In collaboration with Dr. Y. Xiong's lab, we have investigated this possibility by determining the RNA and protein levels of p21 in TGF-B treated and untreated human kerotinacyte line, HaCaT, which is highly sensitive to TGF-B growth inhibition. Results from Northern blot analysis, immunoprecipitation with specific antibodies against p21 as well as cdk4 and cyclin D, and Western blot analysis indicated that p21 level is increased significantly by TGF-B treatment. We have further demonstrated that TGF-3 causes a rapid and significant transcriptional induction of the p21 promoter. These results suggest that p21 as a vital regulator of the cell cycle progression, can respond to both intracellular signals, such as DNA damage, and extracellular signals, such as TGF-B. Previous findings have implicated p27KiPl as an effector mediating the TGF-B growth inhibitory effect. More recently, p15, or MTSII (multiple tumor suppressor II), is induced in the same HaCaT cell line upon TGF-B treatment. Taken together these results demonstrate that a single extracellular antiproliferative signal, TGF-B, can act through multiple signaling pathways to elicit a growth arrest response (ref. 4) . Our recent studies have further demonstrated that TGF-B may act through a single pathway involving the transcription factor Spl and its family members to activate both the p21 and p15 promoters (ref.
5,6).
We have since extended the study of TGF-B regulation on cell cycle control to mammary epithelial cells to determine whether p21, p15, or p27 serve as downstream effectors for the TGF-B growth inhibitory signal. We are currently using two mammary cell lines as model systems in the study: the human MCF-7 cells and the TGF-B type II receptor transfectants derived from them as described above; and the mouse NMuMG cells derived from normal mammary gland (CRL 1636) which have been shown to be responsive to TGF-B growth inhibitory signal. Any potential similarities and differences between the two types of cells in TGF-B signal transduction may provide us with a unique opportunity to dissect and elucidate the complex functional interactions among those molecules and their potential roles in breast tumorigenesis. Our preliminary results indicate that the p21 protein was induced by TGF-B in the RII transfectant of MCF-7 cells (data not shown), suggesting the TGF-B mediated growth arrest in MCF-7 breast cancer cells is potentially mediated by p21. In the immediate future, we will focus our effort on three specific questions: 1. whether the levels and/activities of p21, p15, or p27 are induced upon TGF-B treatment; 2. if p21 and/or p15 is induced, whether the TGF-B signal acts to transcriptionally activate their promoters; 3. whether a common TGF-B responsive element is contained in the p21 and the p15 promoters. Based on the results generated in those studies, we will determine whether the action of estrogen affects the induction or activation of these Cdk inhibitors. We will also use antiestrogens in those studies to determine the effects observed are specific for the action of estrogen. The breast cancer cell line SKBR3 will be used as a negative control in those analyses.
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C. CONCLUSIONS
The findings that the loss of type II TGF-13 receptor is closely associated with the tumorigenic phenotype in both breast and colon carcinomas strongly support the notion that the TGF-B growth-inhibitory signal may play an important role in maintaining a normal control in cell proliferation. Alterations in the expression of this key component, RII, consists a key step in the multistep process of carcinogenesis. Moreover, a restoration of the RII expression in these tumor cells may reconstitute the negative-growth loop and consequently reverse the tumorigenic phenotype of the cancerous cells. Further studies in this direction, particularly in combining with the original proposed analysis of the estrogen effect on the expression of R11 in breast epithelial cells, will yield valuable information regarding the molecular events controlling both the normal and malignant growth of those cells.
The lack of specific reagents, the high titer antibodies against the two types of TGF-B receptors, has limited the progress in undertaking the tasks of histological studies of preisolated breast carcinoma specimens and the examination of TGF-B receptor content in both breast cell lines and primary cell cultures. However, our effort in overcoming this difficulty has yielded promising preliminary results and significant progress could be made in the coming years in addressing those questions. In the meantime, we have made significant progress in establishing a biological system in which the important question of how the two antagonizing growthregulatory pathways of TGF-B and estrogen interact in breast epithelial cells.
The findings that the inhibitors to the cyclin-dependent kinases, p15 and p21, may serve as effectors for the TGF-B growth inhibitory pathway opens a great opportunity in studying cell cycle control in breast epithelial cells. Current studies focus on the dissection and elucidation of the signaling pathway linking the TGF-B receptors at the plasma membrane and the cell cycle control machinery in the nucleus , as well as the point where estrogen may interfere with the signaling. Results from further analysis in this direction will not only significantly contribute to an understanding of the molecular events leading to breast carcinogenesis, but also aid in the development of new therapeutics for breast cancer. 
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The role of transforming growth factor (TGF) 3 type II nique to suppress autocrine TGFP activity in two colon carcireceptor in reversing the malignant phenotype of hu-noma cell lines . Repression of endogeman breast cancer MCF-7 cells was examined. MCF-7 nous TGFP3 expression by antisense TGF/3 1 RNA increased cells were insensitive to TGFI3 and expressed undetecttumorigenicity in nude mice by the transfected colon carcinoma able levels of cell surface TGFI3 type I receptor (RI) and cell lines. These results suggested that loss of autocrine TGFI type II receptor (RI) by cross-linking with 12 5 I-TGFI3r. activity contributes to malignant progression and implied that Stable transfection of a RII expression vector yielded 3 restoration of TGF3 responsiveness in cells which had lost transfectants with varying levels of exogenous R11 the capacity for inhibition could lead to reversal of malignant mRNA and protein levels. Expression of RIl also inprogression. creased TGF1I3 binding to RI in all 3 clones. Proliferation TGFps elicit their effects by binding to cell surface receptors. of RII-positive clones was inhibited by exogenous TGF1I3
Three major types of TGFO-binding proteins are known to be in a dose-dependent manner, whereas the control clones widely distributed in most TGFO-responsive cells. They are remained TGF13-insensitive. The RII transfectants were referred to as type I (RI), type II (RII), and type III or 3-glycan growth arrested in monolayer culture at saturation den-(RIII). RI and RII are glycoproteins of 53-and 75-kDa, respecsities which were 41-66% of that of the Neo controls.
tively, whereas RIII is a proteoglycan of 280-330 kDa (MasThey also showed reduced clonogenicity in soft-agarose. sagun, 1990, 1992) . Molecular cloning and functional analyses Tumorigenicity in ovariectomized, estrogen-supplehave shown that both RI and RII are serine/threonine kinase mented nude mice was delayed in transfectants with low receptors necessary for TGF3 signal transduction (Lin et al., RII levels. Transfectants expressing high levels of RII 1992; Franz6n et al., 1993; Bassing et al., 1994; Wrana et al. , showed a large reduction in tumorigenicity as well as a 1992). Sequence analysis of RIII revealed that it has a large longer delay in tumor formation. Tumor growth was as-extracellular domain with a relatively small cytoplasmic dosociated with loss of exogenous RII expression in trans-main that contains no obvious signaling motif (Lopez-Casillas fectants. The results indicate that when systems for et al 1991; Wang et al., 1991) . Recent studies showed that RIII TGF13 signal transduction are intact, reconstitution of is involved in ligand presentation to TGFP signaling receptors lignancy in cells lacking R.l (Lopez-Casillas et al., 1993; . Thus, direct involvement of RI and RII in TGF3 signal transduction would suggest that loss of functional RI and/or RII expression Tr-ansforming growth factor p3 (TGF() 1 has been shown to could also contribute to the loss of autocrine TGFP activity regulate cell differentiation, proliferation, and extracellular resulting in tumor progression. Several TGF3-resistant cell lines  matrix formation (Massagud, 1990; Moses et al., 1990; Roberts Arteaga et al., 1988) have been shown to have low or undetectand Sporn, 1991). Although in most systems active TGF3 repablet al.
1988)
cenls ar e of or undetect -resents a small percentage of total secreted TGF3, it has been able RI and/or Rst . MCF-7 cells are of particular interest in this shon t ac asan utorin-neatie gowt reulaoras evi-regard as the TGFf3 produced by these cells which lack the type shown to act as an autocrine-negative growth regulator al II receptor has been implicated as contributing to progression denced by TGFI3 neutralizing antibody stimulation of several (Arteaga et al., 1993a) .
cell lines (Arteaga et al., 1990; Hafez et al., 1990; , other studies also CA38173 and CA50457 (to M. G. B.), CA60848 (to L. E. G.), and P30CA showed that TGFP, overexpression may have a tumor-promot-43703 to Case Western Reserve University Cancer Center. The first two ing effect. For example, overexpression of active TGFI3 in the authors contributed equally to the work. The costs of publication of this ElA-transformed human embryonic kidney cell line 293 which article were defrayed in part by the payment of page charges. This is insensitive to TGFI growth inhibition resulted in increased article must therefore be hereby marked "advertisement" in accordance tumor incidence and enhanced tumor growth in nude mice with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Performed as part of the requirements for the Ph.D. degree at (Arrick et al., 1992) . In this case and that of MCF-7 cells menMedical College of Ohio.
tioned above, the insensitivity of the malignant cells to TGFp • * To whom correspondence should be addressed. Tel.: 419-381-4324; growth inhibitory effect indicated that the overproduced TGFP3 Fax: 419-382-7395.
'The abbreviations used are: TGF3, transforming growth factor-f3; presumably acted in a paracrine fashion with host cells to pro-FBS, fetal bovine serum; bp, base pair(s); PAGE, polyacrylamide gel mote tumor growth. electrophoresis.
We hypothesized that if the TGFP insensitivity of MCF-7
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Role of TGF3 Receptor in Malignancy cells was due to low TGFP receptor expression, restoration of into pBSK(-) plasmid (Stratagene Cloning Systems). After cutting the expression should restore the sensitivity of the cells to TGF/ plasmid with HinfI, an antisense riboprobe was synthesized in vitro growth inhibitory activity and reduce the malignancy. Since using T. RNA polymerase which protects a 164-bp fragment of RI mRNA during RNase digestion. The RII riboprobe plasmid was con-TGFJ binding to RI requires RII, loss of TGFI binding to both structed by subcloning a piece of RII cDNA from the 5' end of the receptors could in fact be due to the loss of RII expression alone expression vector into pBSK(-) plasmids. This piece of DNA contained, as in the case of chemically-mutagenized mink lung epithelial in addition to 264-bp RII cDNA (NarI-PstI), some of the vector DNA cells (Laiho et al., 1990; Wrana et al., 1992) . Recently, Inagaki sequence (18 bp) which is transcribed into recombinant RII mRNA and co-workers (1993) showed that loss of TGFI sensitivity of when the RII expression vector is transfected into MCF-7 cells. As a result, the transfected RII mRNA could be distinguished from endogea human hepatoma line after continued exposure to low TGF1 1 , nous RII mRNA in RNase protection assays because the antisense riconcentrations was due to loss of the RII gene and transfection boprobe synthesized by T. RNA polymerase in vitro protected a larger of R11 expression vector into the cells restored TGFJ sensitivity, fragment (282 bp) when hybridized with the transfected RII mRNA We now show that re-expression of R11 in MCF-7 cells also than when hybridized with endogenous RII mRNA. restored TGF/ sensitivity. More importantly, the RII-transRNase protection assays were performed as described previously . Briefly, radioactive riboprobes were allowed to hybridize fected cells showed reduced cloning efficiency in soft-agarose with the RI and RII mRNA in 40 pg of total RNA. The hybridization and reduced tumorigenicity in nude mice, indicating that res-mixture was then treated with RNase A and RNase T 1 followed by toration of TGFJ response can lead to reversion of malignancy proteinase K treatment. The protected fragments of the probes were in cells which have lost the capacity to respond to TGF3-neganalyzed by urea-PAGE and visualized by autoradiography. Actin ative regulatory effects.
mRNA protected by an actin riboprobe was used to verify equal sample loading as described previously .
Receptor Cross-linking-Human TGFf3 1 was purchased from R & D MATERIALS AND METHODS Systems (Minneapolis, MN) and iodinated by the chloramine T method Cell Culture-MCF-7 cells were originally obtained from the Michias described by . Binding and cross-linking of gan Cancer Foundation and stored frozen. The cell line was adapted to 200 pm.
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I-TGFj3 to a cell monolayer on 35-mm tissue culture wells McCoy's 5A medium supplemented with 10% fetal bovine serum (FBS), were performed as described by . Labeled cell pyruvate, vitamins, amino acids, and antibiotics (Mulder and Brattain, monolayers were solubilized in 200 Al of 1% Triton X-100 containing 1 1989). Working cultures were maintained at 37 'C in a humidified at-mm phenylmethylsulfonyl fluoride. Equal amounts of cell lysate protein mosphere of 5% CO 2 and routinely checked for mycoplasma contaminawere electrophoresed in 4-10% gradient SDS-PAGE under reducing tion. MCF-7 limiting dilution clones were obtained by diluting the pa-conditions and exposed for autoradiography. Soft-agarose Assay-Soft-agarose assays were performed as decloning site to accept any cDNA to be expressed followed by an SV40 scribed previously to compare the clonogenic potential polyadenylation sequence. The promoter region upstream of the multiof control and RII-transfected cells. Briefly, cells (2 x 10' or 6 x 10') were ple cloning site contains a minimal human cytomegalovirus promoter suspended in 1 ml of 0.4% sea plaque-agarose in McCoy's medium with heptamerized tet-operators. This promoter has no activity without containing 10% FBS and plated on top of a 1-ml underlayer of 0.8% the tTA. However, when the tetracycline repressor of the tTA binds to agarose in the same medium in 35-mm tissue culture plates. The plates the tet-operators, the virion protein 16 domain of the tTA can activate were incubated for 2 weeks in a humidified atmosphere of 5% CO 2 at the minimal human cytomegalovirus promoter activity to a very high 37 'C. Cell colonies were visualized by staining with 1 ml of p-iodolevel, whereas binding of tetracycline to the repressor domain of the tTA nitrotetrazolium violet (Sigma). can almost completely inhibit tTA binding to the promoter. The orienThmorigenicity Study-Cells from exponential cultures of MCF-7 tation of the subcloned RII cDNA was checked by restriction enzyme transfectants were inoculated subcutaneously behind the anterior fore digestion. In order to select stable transfectants, a neomycin-resistant limb of 4-week-old athymic mice (athymic nu /nu-CWRU Cancer Center gene under control of the mouse f-globin promoter was subcloned into athymic mouse colony). Each mouse was inoculated on both sides. Mice the tTA-containing plasmid. This plasmid (1 pg) and the RII-containing had been ovariectomized and 1.7 mg of 170-estradiol 60-day extended plasmid (10 pg) were linearized and transfected into one of the MCF-7 release pellets (Innovative Research of America, Toledo, OH) were limiting dilution clones designated MCF20 with a Bio-Rad electropora-placed subcutaneously as described by Gottardis et al. (1988) 1 week tor at 250 V and 960 microfarads. The control cells were transfected prior to cell inoculation. Mice were maintained in a pathogen-free fawith the Neo-containing plasmid (1 pg) and the cloning plasmid (10 Pg) cility. Growth curves for xenografts were determined by externally measwithout RII cDNA. The transfected cells were plated in 10-cm tissue uring tumors in two dimensions using a caliper. Volume (V) was deterculture plates in McCoy's 5A medium containing 10% FBS for 2 days.
mined by the following equation, where L is length and W is the width Selection of stable transfectants were carried out by adding Geneticin of the xenograft: V = (L x WI) x 0.5. Xenografts were resected from (G418 sulfate; Life Technologies, Inc.) to the medium at 600 pg/ml. After anesthetized mice, flash frozen in liquid nitrogen, and pulverized for 2 weeks, antibiotic-resistant clones were ring-cloned and expanded for total RNA extraction. screening of RII expression. Some of the control clones were ring-cloned and others were pooled. They were designated as MCF 20-Neo clone or RESULTS MCF 20-Neo pool, respectively.
MCF-7 Resistance to Inhibition by TGFf3-Arteaga et al. RNA Analysis-Total RNA from MCF-7 cells in culture and xe- 1988) reported that estrogen receptor-positive breast cancer nografts from tumor-bearing nude mice was extracted by guanidine thiocyanate homogenization and ultracentrifugation through a cesium cells, including MCF-7 cells, were insensitive to TGFJ growth gradient essentially as described by Chirgwin et al. (1979) . In order to inhibitory activity and had reduced TGFJ binding. Since difmeasure RI and RII mRNA levels, we constructed RI and RII riboprobe ferent phenotypes of MCF-7 cells have been observed from difplasmids for RNase protection assays. ferent laboratories (Osborne et al., 1987) , we initially examined A fragment of human RI cDNA (588 bp) was obtained by polymerase the TGFf3 sensitivity of the MCF-7 cells available in this labochain reaction using the sense primer 5'-GACCAGTGTGCTratory. As shown in Fig. 1 , our MCF-7 cells were resistant to TCGTCTGC-3 and the antisense primer 5'-GCTGGCTTTCCTTGGG-TACC-3' according to the sequence published by Franzen et al. (1993) . TGFI 1 whereas mink lung CCL-64 cells showed a dose-dependThe polymerase chain reaction fragment was confirmed to be RI cDNA ent growth inhibition by TGFp. Receptor cross-linking to 1251_ by restriction enzyme analysis and DNA sequencing, and was cloned TGFI 1 revealed that MCF-7 cells did not express detectable 0 c co Monolayer confluent cultures of MCF-7 cells and human fibrosarcoma tions (Fig. 2) . Therefore, the lack of cell surface RI and RII HT1080 cells (used as a positive control) in 35-mm wells were incubated expression was apparently responsible for TGFI3 insensitivity. in the presence of 200 pM I-TGFO3, for 3 h at 4 'C. The receptor-bound This MCF-7 phenotype is essentially the same as that de-iiiI-TGFf3, was cross-linked with disuccinimidyl suberate. Cell lysates scribed by Arteaga et al. (1988 Arteaga et al. ( , 1993a .
were electrophoresed in 4-10% gradient SDS-PAGE under reducing conditions. The i'2I-TGFI3,-linked TGFI3 receptor type I (RI), type II Expression of RII-Since it was shown that TGFp binding to (RII) , and 3-glycan (RIII) were visualized after autoradiography. RI requires RII and overexpression of RII in a TGFP3-resistant hepatoma cell line restored TGFP3 sensitivity , it was possible that the low level of could be competed by 100-fold cold TGFp3, as shown in lanes 4 TGFP binding to RI in MCF-7 cells was merely due to lack of and 8 of Fig. 4 . As expected, addition of tetracycline in the RII expression and restoration of RII alone might restore TGFP3 tissue culture medium for 4 days before the receptor crosssensitivity. Therefore, we transfected tetracycline-regulatable linking assay showed a dose-dependent suppression of RII ex-RII expression plasmids into a MCF-7 limiting dilution clone pression as well as RI binding (Fig. 4, lanes 5, 6, 9 , and 10). designated clone 20. Initial screening for RII positive transfec-Thus, our results also suggest that TGFp3 binding to RI requires tants with RNase protection assays yielded 3 clones (desig-RII in MCF-7 cells. nated MCF 20-RII 1, 8, and 21, respectively) expressing transRestoration of TGFf3 Sensitivity-We next examined whether fected RII mRNA (Fig. 3) . MCF 20-RII 8 expressed the lowest overexpression of RII as well as increased TGFP3 binding to RI level of transfected RII whereas MCF 20-RII 1 expressed the and RII could restore the sensitivity of the transfectants to highest level of RII. The untransfected parental clone (MCF 20) TGF/3 growth inhibitory activity. When the three RII transfecand the control transfectants (MCF 20-Neo pool) expressed a tants were plated in 24-well culture plates in the presence of low level of endogenous RII. It appears that the expression of TGFf3 1 at concentrations from 0.2 to 25 ng/ml for 4 days, DNA the transfected RII increased endogenous RII mRNA levels in synthesis was significantly inhibited in a dose-dependent man-MCF 20-RII 1 and 21. Since it is not possible to distinguish ner (Fig. 5) . The ICe was approximately 0.4 ng/ml for MCF endogenous protein from transfected RII protein, the signifi-20-RII 1, 0.8 ng/ml for MCF 20-RII 21, and 0.9 ng/ml for MCF cance of this RNA band is not clear. However, it does raise the 20-RII 8. The 40% inhibition of clone 1 at 0.2 ng/ml is similar to possibility that the type II receptor can be autoregulated the 50% inhibition of CCL64 cells at this level of TGFP3 expothrough the restoration of the TGFP3 signaling pathway in sure. Although MCF 20-RII 8 had a lower RII expression level MCF-7 cells. All the clones expressed similar levels of RI than MCF 20-RII 1 or MCF 20-RII 21, it appears that this level mRNA. Consistent with mRNA levels, MCF 20-RII 1 also ex-of RII expression is adequate to confer a growth inhibitory pressed a higher level of RII protein than MCF 20-RII 21 as response to exogenous TGFI31 in this type of assay. Both MCF shown by receptor cross-linking assays (Fig. 4, lanes 3 and 7) . 20 and MCF 20-Neo controls were insensitive to the treatment MCF 20-RII 8 expressed the lowest level of RII protein (data with TGFf3 1 over the same range of concentrations as the panot shown). Similar to MCF-7 parental cells, the MCF 20 clone rental MCF-7 cells shown in Fig. 1 . and a MCF 20-Neo clone showed very low levels of both RI and Growth Arrest at Low Cell Density-Growth curves of the RII expression (Fig. 4, lanes 1 and 2) . However, overexpression Neo pool and the three RII transfectants were generated to of RII also increased TGFf3 1 binding to RI as shown in MCF determine whether RII expression led to alteration of growth 20-RII 1 and 21. The increased ... I-TGFO3 binding to RI and RII parameters in tissue culture (Fig. 6) . Growth rates (doubling 
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• 20-A i1 RII sense clones designated MCF 20-RII 8, 21, and 1, respectively, were obtained which expressed increasing amounts of transfected RII mRNA with relatively similar amounts of endogenous R11 and RI mRNA levels. Actin mRNA levels were used to verify equal sample loading. (lanes 1-3  and 7 ) or in the presence of 20 nM cold TGFI3 1 (lanes 4 and 8) for 3 h at 4 'C. For lanes 5, 6, 9 , and 10, the cells were cultured in the presence of density and MCF 20-RII 8 (with the lowest RII expression) had tetracycline at 0.1 or 1 pg/ml for 4 days before the receptor cross-linking the highest cell density among the RII transfected clones. assay. The media were replenished once during the 4-day period. The
Anchorage Independent Growth-To assess the effect of RII receptor-bound I' 25 -TGFp 1 was cross-linked with disuccinimidyl suber-expression on the malignant properties of MCF-7 cells, we comate. Cell lysates containing equal amounts of protein were electrophoresed in 4-10% gradient SDS-PAGE under reducing conditions. The .2.I-pared the ability of the control and RII-transfected cells to form TGFI3 1 -linked TGF/3 receptors were visualized after autoradiography.
colonies in soft-agarose as this property is considered to be reflective of malignancy. Control cells and each of the RII transtime) of the MCF 20-Neo pool and RII transfectants were simfectants were tested for anchorage independent growth in ilar at the exponential growth phase. The growth of the three 6-well culture plates at 2 x 10' and 6 x 10' cells/well. After 2 RII transfectants reached plateau phase on day 9, while the weeks of incubation, culture growth was terminated and cologrowth of the MCF 20-Neo pool reached plateau phase on day nies were visualized by staining with p-iodonitrotetrazolium 11. As a result, the saturation densities of the RII transfectants violet staining. As shown in Fig. 7 , the cloning efficiencies of the were only 41-66% that of the MCF 20-Neo pool on day 11. MCF MCF 20-Neo pool and the MCF 20-Neo clone were similar at 20-RII 1 (with the highest RII expression) had the lowest cell both cell numbers. In contrast, all 3 RII transfectants showed a 
4-clone1
Since the xenografted transfectants were no longer under term Neo selection, it was hypothesized that resumption of tumor -growth might have been due to the loss of expression of ElI. Therefore, total RNA samples were prepared from xenografts FIG. 7. Anchorage independent colony formation in soft-agarat the termination of the experiment and analyzed for erI ose of MOE 20 controls and Rh transfectants. Exponentially growmRNA with a human-specific EII riboprobe. Among the xeing cells (2 x ifm or 6 x 10o) were suspended in 1 ml of 0.4% sea plaque-agarose in Mccoy's 5A medium containing 10% FBS and plated nografts examined, all 3 from MCF 20-EII w and two out of four on top of a 1-ml underlayer of 0.8% agarose in the same medium in from MCF 20-re I 21 had lost transfected ElI expression ( Fig.  6 -well tissue culture plates. After 2 weeks of incubation, cell colonies 9). In addition, the transfected weI mRNA levels were signifiwere visualized by staining with 1 ml ofp-iodonitrotetrazolium violet.
cantly reduced in the other two xenografts from Mex 20-RiI 21.
Thus, it appears the increased tumorigenicity of MCF 20-eRI S significant reduction of cloning efficiency Similar to the patand 21 at the later stages of the xenograft experiment was due tern of reduced saturation density in monolayer growth to reduction or loss of the transfected RII expression. MCF2O-RII 1 showed the greatest reduction of anchorage independent growth while MOF 20-iI 8 showed the least effect DISCUSSION of transfection on cloning efficiency among the 3 clones.
A number of studies have indicated that at least in some Thmorigenicity-sReduction of cloning efficiency in soft-agasituations TGFin can contribute to tumor growth and maligrose suggested to us that restoration of TGFJ3 sensitivity might nancy (Arrick et al., 1992; Steiner and Barrack, 1992 ; Arteaga also render MCF-7 cells less tumorigenic. To test this hypothet al., 1993a; Chang et al., 1993) while others have indicated esis, we inoculated exponentially growing cells of MCF 20-Neo that TGFJ autocrine activity acts in a suppressive manner with pool, MCF 20-RII , and MCF 20-ElI 21 into ovariectomized respect to malignant progression . Most estrogen-supplemented nude mice at 5 x 106 cells per site and of the studies have employed manipulation of autocrine/ followed progression of xenograft formation. MCF 20-Neo pool paracrine TGFI3 activity by manipulating TGF/3 expression. formed xenografts in 10 of 10 inoculation sites and all grew Such studies have thus been focused on the balance between rapidly in estrogen-supplemented nude mice. Xenograft forma-TGFs inhibitory actions on tumor cells versus TGFh effects on tion of the two ed I transfectants was delayed compared to the the microenvironment which might promote tumor growth by a MCF 20-Neo pool (Fig. 8) . Consistent with in vitro data, MCF variety of effects on stromal cells and/or the immune system. In 20-esI S produced progressively growing xenografts at all sites this study we examined the role of Rii in modulating tumor cell inoculated (10/10) while MCF 20-ElI 21 resulted in xenografts growth in the presence of autocrine/paracrine TGFjs. The in 7 of 10 sites. Mean delay in time to xenograft formation >200 MCF-7 cell line provided a good model system for this approach mmt was 11 days for MOF 20-ElI S and 30 days for MCF 20-tio in that it was insensitive to growth inhibitory effects of TGFa 21 compared to the time to xenograft formation by the MCF apparently due to low RII expression (Arteaga et al., 1993a) .
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the cells were growth inhibited in vitro (Steiner and Barrack, 1992) . Another study by Chang et al. (1993) showed that Meth 0 A sarcoma cells were growth inhibited by overexpression of transfected RI active TGF/3 1 in vitro. However, exogenous TGFj3 promoted endogenous RIf Meth A cell tumor growth and the TGF13 1 overexpressing cells were also more tumorigenic in vivo. Arteaga and co-workers (1993b) also reported that an anti-TGF3 antibody which neutralized all three TGFp3 isoforms inhibited TGFI3-sensitive MDA-231 human breast cancer cell tumorigenicity and increased mouse spleen natural killer cell activity. These results -actin led to the suggestion that the net effect of TGFJ3s on tumor growth in vivo is promoting rather than suppressing perhaps i 9edue to in vivo effect on angiogenesis, the expression of extraFIn. 9. RhIIILRNA levels in xenografts. At the termination of the cellular matrix proteins and their cell surface receptors, or the tumorigenicity experiments, total RNA was extracted from randomly selected xenografts formed by MCF 20-Neo pool, MCF 20-RII 8, and local suppression of immune surveillance. MCF 20-RII 21. RNase protection assays were performed using radioOur unpublished data 2 showed that RII expressing clones active [ 22 P]UTP-labeled human RII and actin antisense riboprobes with and Neo controls produced similar levels of TGF)3 1 . Yet, the RII 40 fig of total RNA to determine transfected and endogenous RII mRNA expressing clones were less tumorigenic. It may be that the levels in the indicated xenografts. Actin mRNA levels were used to verify equal sample loading.
increased TGFP receptor expression in MCF-7 cells enhanced autocrine/paracrine TGFf3-negative activity on the tumor cells, Our study showed that overexpression of RII restored TGFJ3 as well as reducing the TGFf3 effect on the microenvironment of sensitivity and reduced the malignancy of MCF-7 cells. Fur-the tumor host by sequestering TGFj3s. Along these lines RII thermore, although the three RII transfectants were similarly expression also led to large increases in cell surface expression sensitive to exogenous TGFP3, proliferative inhibitory effects of type I and type III receptors in transfected cells (Fig. 4) . As (Fig. 5) , their growth patterns in vitro and in vivo were insuch, it may be that the model systems which were shown to be versely related to their transfected RII expression levels. These stimulated in vivo by TGFP3 overexpression lack sufficient results show that at least in MCF-7 cells, TGFJ3 receptor levels TGFj3 receptor expression to sequester the high levels of the play an important role in determining malignant properties.
ligand. However, an intriguing question raised by this study is why the Loss of TGFP3 response has been shown to be associated with cells expressing different TGFI3 receptor levels showed similar tumor development and/or tumor progression in a number of responsiveness to the growth inhibitory effects of exogenous cancer cell lines including squamous carcinoma cells ( , 1988) , colon carcinoma cells (Hoosein et al., 1989) , were sufficient to maximally mobilize the intracellular signal and prostate adenocarcinoma cells (Murphy et al., 1991) . While transduction components when activated by high TGFP3 consome TGFj3-insensitive squamous carcinoma cells and prostate centrations. Therefore, the higher levels of cell surface TGFJ3 adenocarcinoma cells were shown to retain TGFJ3 receptors receptor in MCF 20-RII 1 and MCF 20-RII 21 appear to confer (Masui et al., 1986; Murphy et al., 1991) , the majority of the sensitivity at lower TGFP3 concentrations in vitro. The result of studies showed that loss of TGFJ3 sensitivity was associated tumorigenicity of transfected cells appears to be reflective of with reduced TGFp receptor expression including highly-prothis difference in sensitivity at low TGF/3 concentrations and gressed colon carcinoma cells. It remains to be determined may, therefore, reflect low in vivo concentrations of active whether reduced expression of TGFP3 receptors is the only event TGFJ3 in the tumor microenvironment, contributing to the loss of TGFP3 sensitivity in these cancers. TGFj3 isoforms have been shown to be potent growth inhibHowever, our study indicates that reduced expression of TGF/3 itory agents in several cancer cell lines in vitro (Roberts and type II receptor alone was sufficient to confer TGFj3 insensitivSporn, 1991; Moses, 1992; Brattain et al., 1993) . Studies on the ity and a more malignant phenotype. Therefore, altered TGFj3 role of TGFp3 in controlling tumor cell growth in vivo have been receptor expression is one of the mechanisms by which neoplascontradictory. Overexpression of TGFJ3 1 in TGFI3-insensitive tic cells may undergo malignant progression via the escape of cells has indicated increased tumorigenicity (Arrick et al., 1992;  negative growth regulation by TGF3. Arteaga et al., 1993a) . Twardzik and co-workers (1989) reported that subcutaneous, peritumoral injection of TGF/3 1 and Acknowledgments-We thank Dr. H. Bujard at the University of Heidelberg, Germany, for the tetracycline-controllable expression P2 inhibited the growth and promoted the differentiation of plasmids and Mary E. Schmidbauer for the skillful preparation of the A549 lung cancer cells which are sensitive to TGFJ3 in vitro. We manuscript. showed that suppression of autocrine TGFj3-negative activity by antisense TGF/ ¶3 RNA significantly increased tumorigenic-REFERENCES ity of TGFO3-sensitive colon cancer cell lines, indicating auto-Arrick, B. A., Lopez, A. R., Elfman, F., Ebner, R., Damsky, C. H., and Derynck, R. crine-negative TGFJ3 activity has a role in counteracting tumor (1992) J. Cell Biol. 118, 715-726 progression . In contrast to the above Arteaga, C. L., TandonA. K.,VonHoff, D. D., and Osborne, C. K. (1988) CancerRes. human breast cancer MDA-MB-231 cells which are sensitive to (1993a) Cell Growth & Differ. 4, 193-201 growth inhibitory activity of TGFP3 in vitro (Zugmaier et al., 1991 ' 4-Endogenous RI! Methods." The purified product was then sequenced directly with Sequenase using the antisense primer and electrophoresed on a 6% polyacrylamide, 7 M urea gel. The sequence from this primer covers the -TGF1 polyadenine tract (nucleotides 709-718).
of 161 amino acids, with the terminal 34 amino acids different from the wild type sequence. Similar R11 mutations resulting from 1-and 2-bp deletions within this poly(A) tract have been detected previously in both RER-positive colon cancer cells and primary RER-positive colon cancer tissues . It has been shown that frameshift mutations located in the 5' half of mRNA transcripts can accelerate the decay of W Is mRNAs (Hagan et al., 1995) . This likely accounts for the re-•, • duced RII transcript levels in HCT116 (Fig. 2) (Fig. 3 , from left, NEO transfection control pool for RII mRNA levels by RNase protection assay. Endogenous RI, RII, TGF-13 1 , and transfected RII mRNA levels second, fourth, fifth, and sixth lanes), whereas the cell surface are shown. Actin mRNA levels were used for normalization. receptor expression of RII was undetectable in the NEO pool (Fig. 3, first lane ). It appears that restoration of RII expression RII CLONES 0 increased cell surface expression of RI, which is consistent with previous reports that the presence of RII is required for TGF-p3
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binding to RI . The specificity of RI and RII was shown by competing 12 5 I-TGF-)3, binding to RI and RII cold TGFI 1 + with 50-fold unlabeled TGF-13 1 (Fig. 3, third lane) . This indicated that transfected RII can be expressed and bind ligand in HCT 116. 
2101)
Increased Fibronectin mRNA Expression-We determined whether expression of RII, as well as increased TGF-P binding fibronectin expression (Ignotz and Massagu6, 1986) . Conse- treated with 1.0 and 5.0 ng/ml TGF-p3 for 24 h. Fibronectin transfectants. Receptor cross-linking assays were used to verify cell mRNA levels increased in RI1-transfected cells in a dose-de-surface expression of RI. Confluent monolayer cultures of HCT 116 pendent manner, whereas fibronectin mRNA levels remained NEO pool and RII clones 17, 21, 26, and 37 were incubated with 400 pM the same in the NEO pool cells (Fig. 4) . Similar results were I,5I-TGF-01 alone (from left, first, second, fourth, fifth, and sixth lanes) or in the presence of 20 nM cold TGF-pl (third lane) as described under also observed in RII clone 37. These observations indicated that "Materials and Methods." Electrophoresis of 150 Ag of protein was RII expression in HCT 116 cells restored TGF-01 sensitivity performed (4-10% gradient sodium dodecyl sulfate-polyacrylamide gel of extracellular matrix (ECM)-associated molecules (ECM electrophoresis under reducing conditions). pathway).
Growth Arrest at Low Cell Density-Growth curves for RII and 37 showed a significant reduction of cloning efficiency (38 clones 17 and 37 and the NEO pool were generated to deter-and 22% of that of the NEO pool, respectively). HCT 116 cells mine whether RII expression led to alteration of growth param-expressed high levels of TGF-j3 1 mRNA (Fig. 2) and secreted eters in tissue culture (Fig. 5) . Growth rates in the exponential TGF-P1 protein (0.4 ng/ml/106 cells). Taken together with the growth phase were essentially similar for the NEO pool and RII growth curves, it suggested that endogenous TGF-f3 was acting clones, but some delay in reaching log phase was observed in in an autocrine-negative manner to inhibit cell proliferation. If RII transfectants. The NEO pool had a slightly higher satura-this were true, TGF-0-neutralizing antibody should be able to tion density than the RII-transfected clones, uncouple the TGF-f3 autocrine loop and increase cell proliferaPlating Efficiency Assay--To assess further the effects of RII tion as described previously . TGF-3 1 -expression on cell growth properties, we compared the ability of neutralizing antibody increased RII clone 17 cloning efficiency the control and RII-transfected cells to expand and form coloas reflected by increases in the number and size of colonies nies at low seeding density. As shown in Fig. 6 . RII clones 17 relative to the control antibody-treated RII clone 17 cells ( by MTT staining after 2 weeks of incubation. This was followed by transfectants. HCT 116 NEO pool and RII clone 17 were treated in log suspension in dimethyl sulfoxide. Relative cell numbers were then phase with 0, 1.0, and 5.0 ng/ml TGF-)3 1 for 24 h. Total RNA was determined by the resultant absorbance at 595 nm. Values are the isolated, and RNase protection assay for fibronectin was performed.
means ± S.E. of four replicates. Actin mRNA levels were used for normalization.
1.5
tion. The NEO pool cells formed xenografts in 10 of 10 inoculation sites, and all grew rapidly. Xenograft formation of RII clones 17 and 37 was delayed compared with the NEO pool (Fig. 9) . The time needed to form xenografts of >100 mm 3 was 4 days for the NEO pool and 14 days for RII clones 17 and 37;
E" once formed, RI clones 17 and 37 tumors grew at a slower rate ) and RII clones noma, which are unaggressive and well differentiated, retain 17 (*) and 37 (W). Cells were plated at 1,500 cells/well in 96-well some responsiveness to TGF-P3 growth inhibition, whereas plates in 0.1 ml of serum-free medium. The relative cell number was their highly aggressive counterparts do not (Hoosein et al., determined using the MTT assay (Carmichael et al., 1987) . Values are 1989) . Several studies have shown that the progression from means -± S.E. of 12 replicates. adenomas to carcinomas is accompanied by a reduced responsiveness to the growth inhibitory effects to TGF-13 (Hoosein et 7A). The proliferation of RII clone 17 was stimulated by 60% al., 1989; Manning et al., 1991; Markowitz et al., 1994) . Since after neutralizing antibody treatment, whereas the NEO pool malignant progression in cancer is thought to be related to an showed no significant response (Fig. 7B) . Similar results were accumulation of genetic defects, it was of interest to correlate seen with RI clone 37 (data not shown).
TGF-03 resistance to specific gene mutations or alterations of Anchorage-independent Growth-The ability to form colonies gene expression. An obvious mechanism that can be proposed in soft agarose is reflective of malignant transformation. Therewhen cells develop resistance to TGF-p effects is the loss or fore, to assess the effect of the restoration of autocrine TGF-/3 significant reduction of TGF-03 receptor expression. Our recent activity on the malignant properties of HCT 116 RH transfecstudies showed that TGF-3 RII, but not RI, can be a downtants, we compared the ability of the NEO pool and RII-transstream mutation target in hereditary nonpolyposis colon canfected clones to form colonies in soft agarose. As shown in Fig. cers which are characterized by high incidence of RER. Al-8, RII clones 17 and 37 had a significantly lower cloning effithough inactivation of TGF-P3 RH correlated with DNA repairciency in semisolid medium than the NEO pool.
defective RER colon tumors , it had not Tumorigenicity-Reduction of the ability for anchorage-indebeen shown that the loss of the receptor had a direct impact on pendent growth suggested that restoration of autocrine TGF-P3 the malignant phenotype of the cells. To show that the loss of activity might also render HCT 116 cells less tumorigenic. To RII expression is directly associated with malignancy of heredtest this hypothesis, we inoculated exponentially growing cells itary nonpolyposis colorectal cancer, we restored RH expresof the NEO pool and RH clones 17 and 37 into nude mice at 5 sion in HCT 116 cells. Our results showed that RII expression x 106 cells/site and followed progression of xenograft formaled to reconstitution of a TGF-03 autocrine-negative loop in HCT 22048 7 . Autocrine TGF-13 activity in HCT 116 R11 transfectants. HCT 116 NEO pool and RII clone 17 cells were plated in 24-well plates at 300 cells/well in the presence of 10 Ag/ml normal IgG or 10 Ag/ml TGF-3 1 -neutralizing antibody. Cell colonies were stained and photographed, and the relative cell number was determined as described in means ± S.E. of 10 xenografts. Experiments for RIJ clones 17 and 37 In addition to restoration of autocrine-negative activity, the were performed at different times; consequently, the NEO control for RiI-transfected cells displayed sensitivity to exogenous TGF-3 each experiment is shown. for induction of the ECM pathway. However, RII-transfected cells were insensitive to growth inhibition by exogenous TGF-/3 116 cells may have a low potential for induction of cdk inhibi-(data not shown). Segregation of growth inhibition and ECM tors such as p15 or p27 (Ewen et al., 1993;  Hannon and Beach, protein induction in response to exogenous TGF-13 has been 1994; Polyak et al., 1994a; Slingerland et al., 1994 ) which observed in other colon carcinoma cells (Geiser et al., 1992) as allows for saturation of the pathway by autocrine-negative well as other model systems (Ebner et al., 1993) . As such, the TGF-f3 activity. Presumably, the ECM pathway would not be TGF-03 signal transduction pathways for these two types of dependent upon the induction of these inhibitors but rather TGF-3 responses may diverge downstream of receptor binding, upon specific transactivation factors associated with ECM moland the effectors of ECM induction may be more sensitive than ecule transcription (Polyak et al., 1994b) . growth inhibition effectors. The ECM response is completely Our finding that the tumorigenicity of HCT 116 is reversible absent from untransfected HCT 116 cells, whereas RII clone 26 upon restoration of wild type RII expression establishes that with a low level of exogenous RII expression showed only 20% RII is a tumor suppressor gene in RER colon cancer. Thus the as much induction of fibronectin as RII clones 17 and 37 folinactivation of RII in HCT 116 by a 1-base truncation of a lowing TGF-3 treatment. Thus, the ECM response appears to polyadenylate sequence is an event that directly promotes tube a function of available receptors in this model system. Ex-mor progression. Deletions and insertions in repetitive DNA ogenous TGF-p may not be inhibitory because the pathways sequences are characteristic of RER tumors (Ionov et al., 1993 ; capable of transducing the inhibitory pathway are saturated by Aaltonen et al., 1993; Kim et al., 1994) , and the shortening of the endogenous TGF-03 produced by HCT 116 RII-transfected polyadenylate sequences in RER tumors is particularly comcells, whereas pathways capable of transducing the ECM pathmon (Chen et al., 1995) . The occurrence of a polyadenylate tract way are not saturated by these levels of TGF-13 and hence are within the RII coding region thus renders it particularly vulcapable of responding to exogenous TGF-/3 1 . For example. HCT nerable to mutation in a cell with the RER mutator phenotype.
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